Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.Methods: Case series.Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.

Iannetta, M., Cesta, N., Stingone, C., Malagnino, V., Teti, E., Vitale, P., et al. (2020). Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 45, 102442 [10.1016/j.msard.2020.102442].

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Iannetta, Marco
;
Malagnino, Vincenzo;Teti, Elisabetta;Landi, Doriana;Marfia, Girolama Alessandra;Andreoni, Massimo;Sarmati, Loredana
2020-10-01

Abstract

Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.Methods: Case series.Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
ott-2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Multiple Sclerosis
Pandemics
COVID-19
DMD
DMT
Disease modifying therapies
IL-6
MS
Adult
Antibodies, Monoclonal, Humanized
Betacoronavirus
Coronavirus Infections
Female
Humans
Immunologic Factors
Male
Middle Aged
Pneumonia
Pneumonia, Viral
Immunocompromised Host
Iannetta, M., Cesta, N., Stingone, C., Malagnino, V., Teti, E., Vitale, P., et al. (2020). Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 45, 102442 [10.1016/j.msard.2020.102442].
Iannetta, M; Cesta, N; Stingone, C; Malagnino, V; Teti, E; Vitale, P; De Simone, G; Rossi, B; Ansaldo, L; Compagno, M; Spalliera, I; Di Lorenzo, A; La...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 2.48 MB
Formato Adobe PDF
2.48 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.pdf

solo utenti autorizzati

Licenza: Non specificato
Dimensione 2.48 MB
Formato Adobe PDF
2.48 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/257266
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact